James Francum

Background

About James Francum

You can spend 10–15 years developing a life-saving drug. You can invest more than $2 billion.And the FDA can stop everything with one document: a Warning Letter. In a single moment: • Product launches stop• Investor confidence drops• Trust with regulators disappears And most companies never see it coming. Not because the science is wrong, but because the organization behind the product is not built for FDA scrutiny. What we repeatedly see inside Pharma and Biotech companies: • QA teams overloaded and forced into firefighting• FDA regulations misunderstood or poorly translated into operational processes• Digital systems that cannot defend data integrity during inspection• Missing project structures that ensure continuous inspection readiness When regulators arrive, these weaknesses become visible immediately. The good news: After helping more than 100 Pharma and Biotech teams prepare for FDA inspections, we identified a clear pattern of what actually works. Companies that succeed in inspections do three things well: They translate FDA expectations into clear operational processes They build defensible data integrity across digital systems They position QA as a strategic driver of approval success When this foundation exists, inspections look very different: • approvals move forward instead of stopping• regulators trust the data• products reach patients without regulatory surprises To make this practical, we documented the full framework in a detailed guide. The guide explains how Pharma and Biotech companies can build inspection-ready organizations and eliminate the hidden compliance gaps that lead to critical findings and Warning Letters. If you'd like a copy of the guide, send me a message and I will share it with you. It’s free.